Vivimed Labs share news, announcements and annual reports
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Vivimed Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2005
Last close ₹5.53down ₹0.11 (1.95%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹5.64.
30 Oct: open ₹5.62, high ₹5.64, low ₹5.53
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹46 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,267
Vivimed Labs share news and announcements
642 announcements, routine notices left out, newest first. Page 5 of 13.
Mar 2021
8 Mar · Business
4 Mar · Business
Feb 2021
13 Feb · Results
1 Feb · Board meeting
Jan 2021
Dec 2020
30 Dec · Updates
30 Dec · Meeting
22 Dec · Corrigendum
14 Dec · Updates
4 Dec · Board meeting
Nov 2020
18 Nov · Results
14 Nov · Results
Oct 2020
8 Oct · Meeting
Aug 2020
29 Aug · Results
20 Aug · Board meeting
13 Aug · Board meeting
1 Aug · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jul 2020
25 Jul · Results
13 Jul · Board meeting
Jun 2020
22 Jun · Board meeting
May 2020
Apr 2020
13 Apr · Legal
Clarification by Vivimed Labs Limited Significant price movement has been observed in Vivimed Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Vivimed Labs Limited has vide its letter inter-alia stated, Dear Sir/Madam, we wish to state that in compliance with the requirements of Regulation 30 of theSEBI (LODR) Regulations, 2015, we have regularly intimated to the Exchange, all the events,information etc. that have a bearing on the operations / performance of the Company, whichinclude all price sensitive information. We also wish to confirm that other than what we have already disclosed, from time to time,currently there is no further material event / information, which requires disclosure pursuant to the SEBI (LODR) Regulations, 2015. We trust the above clarifies the matter With RegardsYugandhar KopparthiCompany SecretaryVivimed Labs Ltd9 Apr · Legal
Significant movement in price has been observed in Vivimed Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Mar 2020
Feb 2020
26 Feb · Meeting